钙通道阻滞剂中毒的体外治疗:EXTRIP工作组的系统评价与推荐
EXTRIP工作组通过系统评价文献,评估体外治疗(ECTR)对钙通道阻滞剂(CCB)中毒的疗效。共纳入83篇文献,含6项体外实验、1项动物实验、55例病例报告或病例系列、19项药代动力学研究、1项队列研究和1项系统评价。药代/毒代数据涉及210例患者,临床分析涉及78例CCB中毒患者。标准治疗(包括高剂量胰岛素-正常血糖治疗)未系统实施。临床数据未提示ECTR改善结局,工作组据此推荐反对对氨氯地平、地尔硫䓬或维拉帕米严重中毒患者在标准治疗基础上加用ECTR(强推荐,极低质量证据1D)。
要点
- EXTRIP工作组推荐反对对氨氯地平、地尔硫䓬或维拉帕米严重中毒患者在标准治疗基础上加用体外治疗(强推荐,极低质量证据1D)。
- 氨氯地平、贝普地尔、地尔硫䓬、非洛地平、伊拉地平、米贝地尔、硝苯地平、尼索地平和维拉帕米被认定为不可透析,证据水平不一。
- 尼卡地平和尼群地平无法进行透析性分级。
- 药代/毒代数据涉及210例患者(氨氯地平32例、地尔硫䓬20例、维拉帕米52例);临床分析涉及78例CCB中毒患者(氨氯地平32例、地尔硫䓬16例、维拉帕米23例)。
- 标准治疗(包括高剂量胰岛素-正常血糖治疗)未系统实施,临床数据未提示ECTR改善结局。
适用人群与场景
- 严重氨氯地平、地尔硫䓬或维拉帕米中毒患者(临床分析共78例,其中氨氯地平32例、地尔硫䓬16例、维拉帕米23例)。
- 药代/毒代数据涉及210例患者(氨氯地平32例、地尔硫䓬20例、维拉帕米52例)。
处置流程与药物剂量
- EXTRIP工作组推荐反对对氨氯地平、地尔硫䓬或维拉帕米严重中毒患者在标准治疗基础上加用体外治疗(强推荐,极低质量证据1D)。
- 标准治疗包括高剂量胰岛素-正常血糖治疗,但原文指出该治疗未系统实施。
研究设计与关键结果
- 系统评价共纳入83篇文献:6项体外实验、1项动物实验、55例病例报告或病例系列、19项药代动力学研究、1项队列研究、1项系统评价。
- 氨氯地平、贝普地尔、地尔硫䓬、非洛地平、伊拉地平、米贝地尔、硝苯地平、尼索地平和维拉帕米被认定为不可透析,证据水平不一;尼卡地平和尼群地平无法进行透析性分级。
- 临床分析纳入78例CCB中毒患者(氨氯地平32例、地尔硫䓬16例、维拉帕米23例),标准治疗(包括高剂量胰岛素-正常血糖治疗)未系统实施,临床数据未提示ECTR改善结局。
证据类型、等级与局限
- 证据类型:EXTRIP工作组系统评价与推荐。
- 推荐强度:强推荐,极低质量证据(1D)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对氨氯地平、地尔硫䓬或维拉帕米严重中毒患者,不应在标准治疗基础上常规加用体外治疗(EXTRIP工作组强推荐,极低质量证据1D)。
- 其他CCB中毒因临床数据不足,工作组未起草推荐,但工作组认为其透析性低且缺乏ECTR的生物学合理性。
指南或共识出处
- EXTRIP工作组系统评价与推荐(发表于Clinical Toxicology (Phila))。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Calcium channel blockers (CCBs) are commonly used to treat conditions such as arterial hypertension and supraventricular dysrhythmias. Poisoning from these drugs can lead to severe morbidity and mortality. We aimed to determine the utility of extracorporeal treatments (ECTRs) in the management of CCB poisoning.
METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, summarized findings, and formulated recommendations following published EXTRIP methods.
RESULTS: A total of 83 publications (6 in vitro and 1 animal experiments, 55 case reports or case series, 19 pharmacokinetic studies, 1 cohort study and 1 systematic review) met inclusion criteria regarding the effect of ECTR. Toxicokinetic or pharmacokinetic data were available on 210 patients (including 32 for amlodipine, 20 for diltiazem, and 52 for verapamil). Regardless of the ECTR used, amlodipine, bepridil, diltiazem, felodipine, isradipine, mibefradil, nifedipine, nisoldipine, and verapamil were considered not dialyzable, with variable levels of evidence, while no dialyzability grading was possible for nicardipine and nitrendipine. Data were available for clinical analysis on 78 CCB poisoned patients (including 32 patients for amlodipine, 16 for diltiazem, and 23 for verapamil). Standard care (including high dose insulin euglycemic therapy) was not systematically administered. Clinical data did not suggest an improvement in outcomes with ECTR. Consequently, the EXTRIP workgroup recommends against using ECTR in addition to standard care for patients severely poisoned with either amlodipine, diltiazem or verapamil (strong recommendations, very low quality of the evidence (1D)). There were insufficient clinical data to draft recommendation for other CCBs, although the workgroup acknowledged the low dialyzability from, and lack of biological plausibility for, ECTR.
CONCLUSIONS: Both dialyzability and clinical data do not support a clinical benefit from ECTRs for CCB poisoning. The EXTRIP workgroup recommends against using extracorporeal methods to enhance the elimination of amlodipine, diltiazem, and verapamil in patients with severe poisoning.
参考来源
- Wong A, Hoffman RS, Walsh SJ, et al. Extracorporeal treatment for calcium channel blocker poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Phila). 2021. PMID: 33555964. doi:10.1080/15563650.2020.1870123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。